The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.
 
Makoto Ueno
Honoraria - AstraZeneca; Chugai Pharma; Merck Serono; MSD; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma; AstraZeneca (Inst); Chugai Pharma; Delta-Fly Pharma; Eisai (Inst); Incyte (Inst); JPH Clinical Development; Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Chigusa Morizane
Honoraria - Eisai; MSD K.K.; Novartis; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Abbvie; MSD K.K.; MSD K.K.; Novartis; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Eisai (Inst); J-Pharma (Inst); Merck (Inst); ONO PHARMACEUTICAL (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Masafumi Ikeda
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; Micron; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Kentaro Sudo
Honoraria - Ono Pharmaceutical; Yakult Honsha
Research Funding - Bristol-Myers Squibb/Ono Pharmaceutical (Inst); Eisai (Inst); Incyte (Inst)
 
Yoshinori Hirashima
Employment - Ono Pharmaceutical
Stock and Other Ownership Interests - Ono Pharmaceutical
 
Masataka Kuroda
Employment - Ono Pharmaceutical
Patents, Royalties, Other Intellectual Property - I hold a patent on the combination usage of nivolumab and modified folfirinox for pancreatic cancer as the first-line setting.
Travel, Accommodations, Expenses - Ono Pharmaceutical
 
Yuki Fukuyama
Employment - Ono Pharmaceutical
Stock and Other Ownership Interests - Ono Pharmaceutical
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte; Lilly; Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Dainippon Sumitomo Pharma; Eisai; FUJIFILM Toyama Chemistry; Nihon Servier; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Syneos Health/Immunocore (Inst); Taiho Pharmaceutical (Inst)
 
Junji Furuse
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; Kyowa Hakko Kirin; Lilly Japan; Merck; MSD; Mylan; Nihon Servier; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Merck; MSD; Mundipharma; OncoTherapy Science; Ono Pharmaceutical; Takara Bio; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Incyte (Inst); J-Pharma (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)